Immunosuppressants reduce venous thrombosis relapse in Behçet's disease

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2753-2760

  Desbois, A C ^a   Wechsler, B ^a   Resche Rigon, M ^b   Piette, J C ^a   Le Thi Huong, D ^a   Amoura, Z ^a   Koskas, F ^c   Desseaux, K ^b   Cacoub, P ^a   Saadoun, D ^a  

^a CNRS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; THALIDOMIDE;

ADULT; ARTERY THROMBOSIS; ARTHROPATHY; ARTICLE; BEHCET DISEASE; BLOOD VESSEL OCCLUSION; BUDD CHIARI SYNDROME; CAVA VEIN DISEASE; CEREBRAL SINUS THROMBOSIS; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; EYE DISEASE; FEMALE; GENITAL ULCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFERIOR CAVA VEIN OBSTRUCTION; INTRACARDIAC THROMBOSIS; LIMB DISEASE; LONG TERM CARE; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH ULCER; NEUROLOGIC DISEASE; NOSE DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RELAPSE; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; SUPERIOR CAVA VEIN OBSTRUCTION; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VEIN THROMBOSIS;

ADULT; ANTICOAGULANTS; BEHCET SYNDROME; BUDD-CHIARI SYNDROME; COHORT STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84864482808     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34450     Document Type: Article

References (22)

1. Sakane T, Takeno M, Suzuki N, Inaba G,. Behçet's disease. N Engl J Med 1999; 341: 1284-91.
2. Calamia KT, Schirmer M, Melikoglu M,. Major vessel involvement in Behçet's disease: an update. Curr Opin Rheumatol 2011; 23: 24-31.
3. Yazici H, Yurdakul S, Hamuryudan V,. Behçet disease. Curr Opin Rheumatol 2001; 13: 18-22.
4. Sarica-Kucukoglu R, Akdag-Kose A, Kayabal IM, Yazganoglu KD, Disci R, Erzengin D, et al. Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006; 45: 919-21.
5. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behçet's disease. J Rheumatol 1992; 19: 402-10.
6. Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, et al. Behçet's disease in Tunisia: demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol 2007; 25: S58-64.
7. Tohme A, Aoun N, El-Rassi B, Ghayad E,. Vascular manifestations of Behçet's disease: eighteen cases among 140 patients. Joint Bone Spine 2003; 70: 384-9.
8. Kuzu MA, Ozaslan C, Koksoy C, Gurler A, Tuzuner A,. Vascular involvement in Behçet's disease: 8-year audit. World J Surg 1994; 18: 948-53.
9. Duzgun N, Ates A, Aydintug OT, Demir O, Olmez U,. Characteristics of vascular involvement in Behçet's disease. Scand J Rheumatol 2006; 35: 65-8.
10. Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behçet's disease. Arthritis Rheum 2010; 62: 2806-12.
11. Radke PW, Schwarz ER, Groesdonk H, Graf J, Janssens U,. Thrombosis in Behçet's disease: report of a case followed by a systematic review using the methodology of evidence-based medicine. J Thromb Thrombolysis 2001; 11: 137-41.
12. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009; 68: 1528-34.
13. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
14. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
15. Geskus RB,. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics 2011; 67: 39-49.
16. Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112: 37-43.
17. Leiba M, Seligsohn U, Sidi Y, Harats D, Sela BA, Griffin JH, et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis 2004; 63: 1445-9.
18. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS,. Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27: 201-5.
19. Mehta P, Laffan M, Haskard DO,. Thrombosis and Behçet's syndrome in non-endemic regions. Rheumatology (Oxford) 2010; 49: 2003-4.
20. Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9.
21. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M,. Budd-Chiari syndrome: a common complication of Behcet's disease. Am J Gastroenterol 1997; 92: 858-62.
22. Bismuth E, Hadengue A, Hammel P, Benhamou JP,. Hepatic vein thrombosis in Behçet's disease. Hepatology 1990; 11: 969-74.